Kx2-361

Kx2-361

SCHEMBL254057

O=C(Cc1ccc(-c2ccc(N3CCOCC3)cc2)cn1)NCc1cccc(F)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 5/20 1.00
TUBB4A P04350 5/20 0.58
TUBB P07437 5/20 0.58
TUBA3C P0DPH7 5/20 0.58
TUBA1B P68363 5/20 0.58
TUBA4A P68366 5/20 0.58
TUBB4B P68371 5/20 0.58
TUBB3 Q13509 5/20 0.58
TUBB2A Q13885 5/20 0.58
TUBB8 Q3ZCM7 5/20 0.58
TUBA3E Q6PEY2 5/20 0.58
TUBA1A Q71U36 5/20 0.58
TUBA1C Q9BQE3 5/20 0.58
TUBB6 Q9BUF5 5/20 0.58
TUBB2B Q9BVA1 5/20 0.58
TUBB1 Q9H4B7 5/20 0.58
ABL1 P00519 1/20 0.58
LYN P07948 1/20 0.58
BCR P11274 1/20 0.58
ERCC1 P07992 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Kx2-361 SCHEMBL29385376 1.00 SRC (1.00) SRCTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL11917539 0.92 SRC (0.85) SRCTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL10084852 0.91 SRC (0.84) SRCTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL19867220 0.90 SRC (0.82) SRCTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL11917548 0.90 SRC (0.82) SRCTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL23761959 0.90 SRC (0.82) SRCTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL20286612 0.90 SRC (0.81) SRCTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL254399 0.90 SRC (0.81) SRCTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL12158487 0.90 SRC (0.81) SRCTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL11917549 0.90 SRC (0.81) SRCTUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 WO disclosed
CN-115477608-B Tubulin inhibitor and preparation method and application thereof 成都贝诺科成生物科技有限公司 2023-12-12 CN disclosed
CN-114516832-B Tubulin inhibitor and preparation method and application thereof 成都贝诺科成生物科技有限公司 2023-11-28 CN disclosed
US-20230167060-A1 COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE ATHENEX, INC. 2023-06-01 US disclosed
US-20230167060-A1 COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE ATHENEX, INC. 2023-06-01 US disclosed
US-20230167060-A1 COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE ATHENEX, INC. 2023-06-01 US disclosed
CN-115477608-A Tubulin inhibitor and preparation method and application thereof 成都贝诺科成生物科技有限公司 2022-12-16 CN disclosed
CN-114516832-A Tubulin inhibitor and preparation method and application thereof 成都贝诺科成生物科技有限公司 2022-05-20 CN disclosed
US-11325885-B2 Method for treating stomach cancer KING ABDULAZIZ UNIVERSITY (SA) 2022-05-10 US disclosed
US-20100249130-A1 BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS, LLC (US) 2010-09-30 US disclosed
WO-2008127728-A1 BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS, LLC (US) 2008-10-23 WO disclosed
WO-2008002676-A9 BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS LLC (US) 2008-07-03 WO disclosed
WO-2008002676-A2 BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS, LLC (US) 2008-01-03 WO disclosed
US-7300931-B2 Compositions for treating cell proliferation disorders KINEX PHARMACEUTICALS, LLC (US) 2007-11-27 US disclosed
US-7300931-B2 Compositions for treating cell proliferation disorders KINEX PHARMACEUTICALS, LLC (US) 2007-11-27 US disclosed
US-20070197783-A1 Compositions and methods of treating cell proliferation disorders SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) 2007-08-23 US disclosed
US-20070197783-A1 Compositions and methods of treating cell proliferation disorders SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) 2007-08-23 US disclosed
US-20070015752-A1 Biaryl compositions and methods for modulating a kinase cascade SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) 2007-01-18 US disclosed
US-20070015752-A1 Biaryl compositions and methods for modulating a kinase cascade SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015752-A1 Biaryl compositions and methods for modulating a kinase cascade MAP3K3, MAP3K2, MAP3K20 SRC 76/4885TUBB4A 2391/4885TUBB 2092/4885
US-20230167060-A1 COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE MAP3K1, MAP3K6, MAP3K11 SRC 96/4885TUBB4A 3755/4885TUBB 3519/4885
US-11325885-B2 Method for treating stomach cancer TUBB, TUBB1, TUBA1C SRC 5/4885TUBB4A 9/4885TUBB 1/4885
US-20070197783-A1 Compositions and methods of treating cell proliferation disorders MKI67, CCNC, CCNA1 SRC 430/4885TUBB4A 218/4885TUBB 342/4885
US-20100249130-A1 BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE MAP3K2, MAP3K3, MAP3K6 SRC 112/4885TUBB4A 1470/4885TUBB 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.